INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
https://doi.org/10.14412/1996-7012-2011-655
Abstract
The paper considers the possibilities of suppressing rheumatoid arthritis (RA) activity and progression in the use of infliximab. It discusses its place in the treatment of patients with early- and extended-stage RA with regard to the current international recommendations.
References
1. <div><p>Brandt J., Haibel H., Cornely D. et al. Successful treatment of active ankylosing spondilytis with the tumor necrosis factor alpha monoclonal antibody Infliximab. Arthr Rheum 2000;43:1346-52.</p><p>Provenzano G., Termini A., le Moli C. et al. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. Ann Rheum Dis 2003;62:680-1.</p><p>D'Haens G., van Deventer S., van Hogenaz R. et al. Endoscopic and histological healing with infliximab anti-TNF antibodies in Crohn's disease: a European multicenter trial. Gastroent 1999;116:1029-34.</p><p>Bartolucci P., Ramanoclina J., Cohen O. et al. Efficacy of the anti-TNF-αantibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatol 2002;41:1126-32.</p><p>Honkanen V.E.A., Tynjala P., Vahasalo P. et al. Infliximab in juvenile arthritis: 1-year follow-up. ACR 66th Annual Scientific Meeting. New Orleans, 2002;1272.</p><p>Aringer M., Graninger W.B., Steinger G. et al. Safety and efficacy of tumor necrosis factor blockade in systemic lupus erythematosis. Arthr Rheum 2004;50:3161-9.</p><p>Labioche I., Liozon E., Weshler B. et al. Refractory polymiositis responding to infliximab; extended follow-up. Rheumatol 2004;43:531-2.</p><p>Gottenberg J.-E., Merle-Vincent F., Bentaberry F. et al. Anti-tumor necrosis factor therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. A follow-up report to tolerability and efficacy. Arthr Rheum 2003;48:2019-24.</p><p>Ritchlin C.T., Haas-Smith S.A., Li P. et al. Mechanisms of TNF-a and RANKL-mediated osteoclastogenesis and bone resorbtion in psoriatic arthritis. J Clin Invest 2003;111:821-31.</p><p>Charles P., Elliott M.J., Davis D. et al. Regulation of Cytokines, Cytokine in Rheumatoid Arthritis Following Anti-TNF{alpha} Therapy Inhibitors, and Acute-Phase Proteins. J Immunol 1999;163:1521-8.</p><p>Souto-Carneiro M., Mahadevan V., Takada K. et al. Alterations in Peripheral Blood Memory B Cells in Patients with Active Rheumatoid Arthritis are Dependent on the Action of Tumour Necrosis Factor. Arthr Res Ther 2009;11:84.</p><p>Насонов Е.Л. Применение инфликсимаба при ревматических заболеваниях. М., 2005;5.</p><p>Machaul K.L., Chartain N., Lark M. et al. Differential effects of IL-1 and TNF alpha on the expression of stromelisin, collagenase, and their inhibitor, TIMP, in rheumatoid human synovial fibroblasts. Matrix Suppl 1992;1:198-9.</p><p>Haworth C., Brennan D., Chantry D. et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor. Eur J Immunol 1991;21:2575-9.</p><p>Tak P.P., Taylor P.C., Breedveld F.C. et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-αmonoclonal antibody treatment in patients with rheumatoid arthritis. Arthr Rheum 1996;39:1077-81.</p><p>Lupia E., Montatrucchio G., Battaglia E. et al. Role of tumor necrosis factor and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 1996;26:1690-4.</p><p>ACR Subcommittee of Rheumatoid Arthritis Guidelines «Guidelines for the management of rheumatoid arthritis: 2002 update». Arthr Rheum 2002;46:328-46.</p><p>Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthr Care and Res 2008;59:762-84.</p><p>Agrawal S., Misra R., Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 2007;26:201-4.</p><p>Ates A., Kinikli G., Turgay M. et al. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 2007;26:538-45.</p><p>Emery P., Breedveld F.C., Dougados M. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.</p><p>Gossec L., Dougados M., Goupille P. et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004;63:675-80.</p><p>Van Gestel A.M., Revoo M.L.L., van't Hof M.A. et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism criteria. Arthr Rheum 1996;39:34-40.</p><p>Felson D.T., Anderson J.J., Boers M. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthr Rheum 1995;38:727-35.</p><p>Furst D.E., Keystone E.C., Fleischmann R. et al. Update consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69(Suppl. I):i2-i29.</p><p>Smolen J.S., Breedveld F.C., Schiff M.H. et al. A simplified activity index for rheumatoid arthritis for use in clinical practice. Rheumatol 2003;42:244-57.</p><p>Aletaha D., Nell V.P.K., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res 2005;7:796-806.</p><p>Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendation for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.</p><p>Elliott M., Maini R., Feldmann M. et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) in patients with rheumatoid arthritis. Lancet 1994;341:1105-10.</p><p>Elliott M., Maini R., Feldmann M. et al. Repeated therapy with monoclonal antibody to tumor necrosis factor (cA2) in patients with rheumatoid arthritis. Lancet 1994;341:1125-7.</p><p>Kavanaugh A., Cush J., St. Clair E. et al. Anti-TNFαmonoclonal antibody treatment of rheumatoid arthritis with active disease on methotrexate: results of double-blind, placebocontrolled multicenter trial. Arthr Rheum 1996;39(Suppl.):S123.</p><p>Kavanaugh A., Cush J., St. Clair E. et al. Anti-TNFαmonoclonal antibody treatment of rheumatoid arthritis with active disease on methotrexate: results of open label, related dose administration following a single dose, double-blind, placebo-controlled trial. Arthr Rheum 1996;39(Suppl.):S244.</p><p>Maini R., Breedveld F., Kalden J. et al. Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthr Rheum 1998;41:1552-63.</p><p>Maini R., St. Clair E.W., Breedveld F. et al. For the ATTRACT Study GroupInfliximab (chimeric anti-tumor necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;345:1932-9.</p><p>Durez P., Nzeusseu Tukap A., Louwerys B.R. et al. A randomized comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolon and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 2004;63:1069-74.</p><p>Инструкция по применению препарата Ремикейд от 21.04.2006.</p><p>Maini R., Breedveld F., Kalden J.R. et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthr Rheum 2004;50:1051-65.</p><p>Conaghan P.G., Quinn M.A., O'Connor P. et al. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produced long-term remissionArthr Rheum 2002;46:1971-2.</p><p>Shergy W.J., Isern R.A., Cooley D.A. et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheum 2002;29:667-77.</p><p>Lipsky P.E., van der Heijde D.M., St. Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.</p><p>Weinblatt M.E., Keystone E.C., Feldmann M. et al. Adalimumab, a fully human anti-tumor necrosis factor antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthr Rheum 2003;48:35-45.</p><p>Wolbink G.J., Vis M., Lems W. et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthr Rheum 2006;54:711-5.</p><p>Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T. et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumor necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.</p><p>Cohen S.B., Emery P., Greemwald M. et al. Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy: results of a multicenter, randomized, doubleblind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr Rheum 2006;54:2793-806.</p><p>Vander Cruyssen B., van Looy S., Wyns B. et al. Four year follow-up of infliximab therapy in rheumatoid arthritis patients with longstanding refractory disease: attrition and long-term evolution of disease activity. Arthr Res Ther 2006;8:R112.</p><p>Vander Cruyssen D., Durez P., Westhovens R. et al. Seven year follow-up of infliximab (IFX) in rheumatoid arthritis patients refractory to multiple DMARDs treatment: Attrition and long-term clinical effect. Arthr Rheum 2009;61(Suppl. 9):THU0181.</p><p>St. Clair E.W., Wagner C.L., Fasanmade A.A. et al. The relationship of serum Infliximab concentration to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, doubleblind, placebo-controlled trial. Arthr Rheum 2002;46:1451-9.</p><p>Tugwell P., Pincus T., Yocum D. et al. The Methotrexate-Cyclosporine Combination Group. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.</p><p>Kremer J.M., Genovese M.C., Cannon G.W. et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Int Med 2002;137:726-33.</p><p>Vollenhoven R.F., Ernestam S., Geborec P. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomized trial. Lancet 2009;374:459-66.</p><p>Breedveld F.C., Emery P., Keystone E. et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.</p><p>St. Clair E.W., van der Heijde D.M., Smolen J.S. et al. Combination of Infliximab and Methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthr Rheum 2004;50:3432-43.</p><p>Smolen J.S., van der Heijde D.M., St. Clair E.W. et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthr Rheum 2006;54:702-10.</p><p>Vastesaeger N., Xu S., Aletaha D. et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoidd arthritis. Rheumatol (Oxford) 2009;48:1114-21.</p><p>Furst D.E., Keystone E.C., Fleischmann R. et al. Updated consensus on biological agents for the treatment of rheumatic disease, 2009. Ann Rheum Dis 2010;69(Suppl. I):i2-i29.</p><p>Westhovens R., Youcum D., Han J. et al The safety of Infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidites: A large, randomized, placebocontrolled trial. Arthr Rheum 2006;54:1075-86.</p><p>Carroll M.B., Bond M.I. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatic B infection. Semin Artr Rheum 2008;38:208-17.</p><p>Kaur P.P., Chan V.C., Berney S.N. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case report. Clin Rheum 2008;27:1069-71.</p><p>Cansu D.U., Kalifoglu T., Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheum 2008;35:421-4.</p><p>Khana D., Silman M., Furst D.E. Safety of tumour necrosis factor-alpha antagonist. Drug Saf 2004;27:307-24.</p><p>Herrinton L.J., Liu L., Shoor S. et al. Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis. Ann Rheum Dis 2008;67:574-5.</p></div><br />
Review
For citations:
Chichasova NV, Chichasova NV. INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2011;5(1):67-75. (In Russ.) https://doi.org/10.14412/1996-7012-2011-655
Views:
1732
Email this article 